Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma

NCT03376659 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT03376659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03376659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma
Lead sponsor
Georgetown University
Phase
Phase 1/2
Overall status
Terminated
Start date
August 8, 2018
Completion date
August 1, 2023
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, metastatic colorectal cancer, metastatic pancreatic cancer, pancreatic adenocarcinoma